pocketful logo light
pocketful logo light
Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

NSE: NEULANDLAB BSE: 524558

₹16624

(0.99%)

Wed, 27 May 2026, 09:43 pm

mtf coin illustrationMTF 5x

Neuland Laboratories Share Price Live Chart

1 Day

(0.99%)

No Result Found

Summary

  • Market Cap

    21883.81

  • Net Profit

    260.11

  • P/B

    10.22

  • Sector P/E

    34.32

  • P/E

    59.90

  • EV/EBITDA

    36.84

  • Debt/Equity (Industry)

    0.17

  • Interest Cover (Industry)

    18.17

  • ROCE (Industry)

    20.59

  • RONW (Industry)

    17.62

  • ROE

    14.84

  • ROCE

    18.58

  • Debt/Equity

    0.09

  • EPS (TTM)

    283.71

  • Dividend Yield

    0.20

  • Book Value

    1460.31

  • Interest Cover

    34.40

Analysis

all

thumbs up icon

Pros

  • Dividends paid are thoroughly covered by earnings (10.5x coverage).
  • Dividends after 3 years are expected to be thoroughly covered by earnings (15.9x coverage).
  • Cash flow for Neuland Laboratories is expected to increase by more than 50% in 2 years time.
  • Neuland Laboratories's earnings are expected to grow significantly at over 20% yearly.
  • Neuland Laboratories's earnings growth is expected to exceed the India market average.
thumbs up icon

Cons

  • Dividend payments have increased, but Neuland Laboratories only paid a dividend in the past 7 years.
  • Neuland Laboratories has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Neuland Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Neuland Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Neuland Laboratories is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters32.6332.6332.6432.6832.68
FII20.4620.9020.6021.6922.11
DII15.8414.7113.5411.5710.97
Public31.0731.7632.8133.6733.84
Government0.000.000.400.400.40

Read More

Technical Analysis

RSI

59.38

MACD

544.09

50 DMA

14725.22

200 DMA

14827.85

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic21046.6717615.6716309.3314184.6712878.3310753.677322.67
Fibonacci17615.6716305.0215495.3114184.6712874.0212064.3110753.67
Camarilla15946.5215632.0215317.5114184.6714688.4914373.9814059.48

Pivots Level: Classic

R3

+6862.00

21046.67

R2

+3431.00

17615.67

R1

+2124.67

16309.33

14184.67
14184.67
Pivot Point
LTP: 16772

S1

-1306.33

12878.33

S2

-3431

10753.67

S3

-6862

7322.67

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    16728.78

  • 20-EMA

    16385.31

  • 30-EMA

    15973.94

  • 50-EMA

    15374.92

  • 100-EMA

    14840.28

  • 200-EMA

    14440.04

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 May 2026agm
12 May 2026board-meetingsAccounts, Quarterly Results, Final Dividend
09 Feb 2026board-meetingsQuarterly Results
07 Nov 2025board-meetingsQuarterly Results
18 Jun 2025dividendFinal Dividend - Rs. - 1218 Jul 2025
15 May 2025dividend₹12.00 Dividend /Share18 Jul 2025
15 May 2025agm
12 Jun 2024dividendAnnual General Meeting/Dividend - Rs 14 Per Share13 Jul 2024
10 May 2024dividend₹14.00 Dividend /Share13 Jul 2024
10 May 2024agm

Read More

Peer Comparison

Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Read More

Neuland Laboratories Ltd About

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1984

Headquarters

CEO

D Saharsh Rao

Employees

Contact

Website icon

Website

http://www.neulandlabs.com

Email icon

Email

ir@neulandlabs.com

Phone icon

Phone

91-40-30211600

Location icon

Location

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Read More

Neuland Laboratories Ltd Company History

YearHistory
2012
  • Neuland Laboratories Ltd issued rights in the ratio of 5:12.
  • The registered office of the company was shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034.
2013
  • The board recommended a dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
  • Neuland Labs received the 2013 CMO Leadership Award for Regulatory Excellence.
2014
  • Neuland Labs inaugurated a new manufacturing facility constructed for its collaboration with Mitsubishi Healthcare Unit API Corporation.
  • The board recommended a dividend of 30% at Rs. 3 per equity share on a face value of Rs. 10 each.
  • Neuland Laboratories announced rights in the ratio of 4:25.
2016
  • The company entered into a Joint Development Agreement with Phoenix Embassy Techno Zone Private Limited.
2017
  • Neuland Labs completed the acquisition of an API plant.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
AIRAVAT CAPITAL TRUST IIblockBuy88961461205 Sept 2025
AIRAVAT CAPITAL TRUSTblockSell88961461205 Sept 2025
SMALLCAP WORLD FUND INCbulkSell48443415618.1612 Dec 2024
MALABAR INDIA FUND LIMITEDblockSell130000740026 Jun 2024
SMALLCAP WORLD FUND INCblockBuy130000740026 Jun 2024
SMALLCAP WORLD FUND INCbulkBuy130000740026 Jun 2024
MALABAR INDIA FUND LIMITEDbulkSell130000740026 Jun 2024
RAMAMOHAN RAO DAVULURIbulkSell4000005012.4508 Dec 2023
BNP PARIBAS ARBITRAGEbulkSell648933871.3131 Aug 2023
BNP PARIBAS ARBITRAGEbulkBuy708972898.3815 May 2023

Read More

Neuland Laboratories Ltd News

Neuland to attend 360 ONE Capital meet

Neuland Laboratories management will attend the 360 ONE Capital 16th Annual Investor Conference in Mumbai on May 28, 2026.

23 May 2026

companies

Neuland Labs Posts Strong FY26 Results, Declares Dividend

Neuland Laboratories reports consolidated revenue of ₹2,02,298.54 lakhs and net profit of ₹36,399.84 lakhs for FY26, declares ₹34/- per share dividend and plans capacity expansion.

12 May 2026

companies

Neuland Labs Q4FY26 Earnings Call on May 12, 2026

Neuland Laboratories Limited announces Q4FY26 results and earnings call scheduled for May 12, 2026 at 17:30 hrs IST. The pharmaceutical company will release quarterly and annual results.

29 Apr 2026

companies

Davuluri Trust Files FY26 Compliance Certificate

Davuluri Ownership Trust submits annual compliance certificate to BSE and NSE for FY26 under SEBI exemption order, confirming adherence to SAST regulations for Neuland Laboratories shareholding.

09 Apr 2026

government-policy-and-regulation

Neuland Labs Files Q4 FY26 Regulatory Certificate

Neuland Laboratories submitted mandatory SEBI compliance certificate for quarter ended March 31, 2026, through registrar KFin Technologies to stock exchanges and depositories.

02 Apr 2026

companies

Read More